期刊
CLINICAL CANCER RESEARCH
卷 17, 期 9, 页码 2819-2829出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-2986
关键词
-
类别
资金
- Ministry of Education, Culture, Sports, Science and Technology, Japan [17016059, 22240089, 22390118]
- Grants-in-Aid for Scientific Research [17016059, 22240089, 22390118] Funding Source: KAKEN
Purpose: The interleukin-13 receptor alpha 2 (IL-13R alpha 2) is expressed by a variety of human malignant cells. Here, we have examined the constitutive surface expression and the epigenetic regulation of IL-13R alpha 2 by human mesothelioma. We have also investigated the therapeutic effect of the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) and anti-IL-13R alpha 2 monoclonal antibody on mesothelioma xenografts. Experimental Design: Cell surface expression of IL-13R alpha 2 by various lung carcinomas was analyzed using flow cytometry. Therapeutic effects of anti-IL-13R alpha 2 and 5-aza-dC were investigated using antibody-dependent cellular cytotoxicity and proliferation assays and by monitoring the survival of mesothelioma-bearing mice. Results: We found that human malignant mesotheliomas expressed surface IL-13R alpha 2 on their surface and that it was upregulated by treatment with 5-aza-dC. This augmented expression of IL-13R alpha 2 resulted in growth inhibition of the mesothelioma cells when cocultured with anti-IL-13R alpha 2 and effector cells, such as splenocytes and peritoneal exudate cells. The growth inhibition of mesothelioma cells was mediated by IFN-gamma that was only detected in the supernatant when effector cells were exposed to 5-aza-dC-treated tumors in the presence of anti-IL-13R alpha 2. Compared with the control or either regimen alone, in vivo administration of anti-IL-13R alpha 2 in combination with 5-aza-dC significantly prolonged the survival of mice with mesothelioma xenografts. Conclusions: These observations indicate a promising role for IL-13R alpha 2 as a target for antibody treatment in malignant mesothelioma, and, in combination with epigenetic regulation by a DNA methylation inhibitor, suggest the potential for a novel strategy to enhance therapeutic potency. Clin Cancer Res; 17(9); 2819-29. (C)2011 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据